Phase 1/1b trial of BMS-986488, undefined MOA small molecule inhibitor.

This trial evaluates BMS-986488 as monotherapy or in combination with adagrasib, cetuximab, or nivolumab to assess safety, tolerability, and initial anti-tumor activity in patients with advanced, unresectable solid tumors including colorectal, renal, lung, and pancreatic cancers. Conducted by Bristol-Myers Squibb at multiple US and Canadian sites, select cohorts focus on KRAS G12C alterations.